U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
MALVERN, Pa., May 09, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
